Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abcellera Biologics Inc (ABCL)

Abcellera Biologics Inc (ABCL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 927,938
  • Shares Outstanding, K 299,335
  • Annual Sales, $ 28,830 K
  • Annual Income, $ -162,860 K
  • EBIT $ -233 M
  • EBITDA $ -136 M
  • 60-Month Beta 0.81
  • Price/Sales 26.21
  • Price/Cash Flow N/A
  • Price/Book 0.91

Options Overview Details

View History
  • Implied Volatility 93.13% (-33.93%)
  • Historical Volatility 95.08%
  • IV Percentile 29%
  • IV Rank 9.49%
  • IV High 352.21% on 04/08/25
  • IV Low 65.96% on 05/09/25
  • Expected Move (DTE 5) 0.21 (6.85%)
  • Put/Call Vol Ratio 1.35
  • Today's Volume 1,000
  • Volume Avg (30-Day) 2,717
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 73,905
  • Open Int (30-Day) 76,639
  • Expected Range 2.89 to 3.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.16
  • Number of Estimates 5
  • High Estimate -0.06
  • Low Estimate -0.22
  • Prior Year -0.11
  • Growth Rate Est. (year over year) -45.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.74 +12.93%
on 02/05/26
4.85 -36.08%
on 01/22/26
-1.17 (-27.40%)
since 01/13/26
3-Month
2.74 +12.93%
on 02/05/26
4.85 -36.08%
on 01/22/26
-0.52 (-14.36%)
since 11/13/25
52-Week
1.89 +64.02%
on 04/07/25
6.51 -52.42%
on 10/08/25
-0.04 (-1.27%)
since 02/13/25

Most Recent Stories

More News
AbCellera to Present at Upcoming Investor Conferences in March and April 2026

AbCellera (Nasdaq: ABCL) today announced that the Company will present at the following investor conferences: TD Cowen 46th Annual Health Care Conference, March 4,...

ABCL : 3.10 (+5.44%)
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

AbCellera (Nasdaq: ABCL) will announce its full year 2025 financial results on Tuesday, February 24, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time)...

ABCL : 3.10 (+5.44%)
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

AbCellera (Nasdaq: ABCL) today announced that the first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635. ABCL635 is a potential first-in-class...

ABCL : 3.10 (+5.44%)
AbCellera and Bruker Reach Global Settlement of Patent Litigation

AbCellera (Nasdaq: ABCL) today announced that it has entered into a settlement and patent license agreement with Bruker Corporation, resolving the patent litigation between the two companies globally....

ABCL : 3.10 (+5.44%)
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

AbCellera (Nasdaq: ABCL) today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. A live audio webcast of the presentation...

ABCL : 3.10 (+5.44%)
AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera (Nasdaq: ABCL) today announced the appointment of Stephen Quake, D.Phil., to its Board of Directors as an independent director. Dr. Quake is a distinguished scientist, inventor,...

ABCL : 3.10 (+5.44%)
AbCellera Reports Q3 2025 Business Results

AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. ...

ABCL : 3.10 (+5.44%)
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences: Truist Securities BioPharma Symposium, November 6,...

ABCL : 3.10 (+5.44%)
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

AbCellera (Nasdaq: ABCL) will announce its third quarter 2025 financial results on Thursday, November 6, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern...

ABCL : 3.10 (+5.44%)
AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera (Nasdaq: ABCL) today announced the appointment of Sarah Noonberg, M.D., Ph.D., as Chief Medical Officer. Dr. Noonberg, a board-certified physician-scientist, brings over two decades of...

ABCL : 3.10 (+5.44%)

Business Summary

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635 and ABCL575. AbCellera Biologics Inc. is based in Vancouver, Canada.

See More

Key Turning Points

3rd Resistance Point 3.37
2nd Resistance Point 3.29
1st Resistance Point 3.20
Last Price 3.10
1st Support Level 3.03
2nd Support Level 2.95
3rd Support Level 2.86

See More

52-Week High 6.51
Fibonacci 61.8% 4.75
Fibonacci 50% 4.20
Fibonacci 38.2% 3.66
Last Price 3.10
52-Week Low 1.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar